CELEX: 62007CN0472
Language: en
Date: 2007-10-24 00:00:00
Title: Case C-472/07: Reference for a preliminary ruling from the Conseil d'État (Belgium) lodged on 24 October 2007 — Association Générale de l'Industrie du Médicament ASBL, Bayer SA, Pfizer SA, Servier Benelux SA, Sanofi-Aventis Belgium SA v Belgian State

26.1.2008   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 22/22
            
         Reference for a preliminary ruling from the Conseil d'État (Belgium) lodged on 24 October 2007 — Association Générale de l'Industrie du Médicament ASBL, Bayer SA, Pfizer SA, Servier Benelux SA, Sanofi-Aventis Belgium SA v Belgian State
   (Case C-472/07)
   (2008/C 22/41)
   Language of the case: French
   Referring court
   Conseil d'État
   Parties to the main proceedings
   
      Applicants: Association Générale de l'Industrie du Médicament ASBL, Bayer SA, Pfizer SA, Servier Benelux SA, Sanofi-Aventis Belgium SA
   
      Defendant: Belgian State
   Questions referred
   
               1.
            
            
               Since the period for transposition of Council Directive of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems (89/105/EEC) (1) expired on 31 December 1989, must Article 4(1) of that directive be considered to be directly applicable in the domestic legal systems of the Member States?
            
         
               2.
            
            
               May Article 4(1) of Directive 89/105/EEC of 21 December 1988 be interpreted as meaning that the resumption for one year, after an absence of 18 months, of a general price freeze in respect of refundable medicinal products which had lasted eight years exempts the Member State from carrying out a review, when the freeze is resumed, of the macro-economic conditions affected by that freeze?
            
         
               3.
            
            
               Is the review of macro-economic conditions referred to in Article 4(1) of Council Directive 89/105/EEC of 21 December 1988, cited above, to be understood as meaning only review as to whether healthcare expenditure is manageable, or must it also extend to macro-economic conditions in the pharmaceutical industry sector whose products are liable to be made subject to a price freeze?
            
         
               4.
            
            
               May the review of macro-economic conditions referred to in Article 4(1) of Council Directive 89/105/EEC of 21 December 1988, cited above, be based on a general trend or trends, such as, for example, ensuring balance in healthcare, or must it be based on more specific criteria?
            
         
      (1)  OJ L 40 of 11.2.1989, p. 8.